Celltrion, Inc. (068270.KS)
- Previous Close
151,800.00 - Open
152,300.00 - Bid 154,400.00 x --
- Ask 154,500.00 x --
- Day's Range
152,300.00 - 156,300.00 - 52 Week Range
152,300.00 - 200,952.38 - Volume
344,284 - Avg. Volume
517,866 - Market Cap (intraday)
33.592T - Beta (5Y Monthly) 0.58
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Aug 5, 2025 - Aug 11, 2025
- Forward Dividend & Yield 714.29 (0.45%)
- Ex-Dividend Date Dec 27, 2024
- 1y Target Est
230,654.77
Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets biopharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P44 that is in phase 3 clinical trial for the treatment of multiple myeloma; CT-P51, which is in phase 3 clinical trial for the treatment of Melanoma, lung cancer; CT-P53, which is in phase 3 clinical trial for the treatment of multiple sclerosis; and CT-P55 that is in phase 3 clinical trial for the treatment of Psoriasis. Celltrion, Inc. was founded in 2002 and is headquartered in Incheon, South Korea.
www.celltrion.comRecent News: 068270.KS
View MorePerformance Overview: 068270.KS
Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 068270.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 068270.KS
View MoreValuation Measures
Market Cap
33.05T
Enterprise Value
34.10T
Trailing P/E
74.23
Forward P/E
32.68
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.82
Price/Book (mrq)
1.90
Enterprise Value/Revenue
9.59
Enterprise Value/EBITDA
31.87
Financial Highlights
Profitability and Income Statement
Profit Margin
11.88%
Return on Assets (ttm)
1.50%
Return on Equity (ttm)
2.41%
Revenue (ttm)
3.56T
Net Income Avi to Common (ttm)
422.69B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
1.14T
Total Debt/Equity (mrq)
12.47%
Levered Free Cash Flow (ttm)
513.07B